Drug Trial Radar · NCT04052737
PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Jan 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Mar 23, 2018
Primary completion
Dec 20, 2022
Study completion Jan 6, 2023
Sponsor
- Lead sponsor
- Pharmazz, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 45 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicentric, randomized, double blind, placebo controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 therapy along with standard supportive care in subjects with mild to moderate Alzheimer's disease.
Conditions
- Alzheimer Disease
- Dementia
Interventions
Normal Saline along with standard treatmentDrug
PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients. In this arm normal saline along with standard treatment will be given for active comparison.
PMZ-1620 (sovateltide) along with standard treatmentDrug
PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of PMZ-1620 related adverse eventsTime frame: 160 days
- Number of patients not receiving full treatment due to intolerance to PMZ-1620Time frame: 160 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Post Graduate Institute of Medical Education and Research
Chandigarh, India
King George's Medical University
Lucknow, India
Sanjay Gandhi Post Graduate Institute of Medical Sciences
Lucknow, India
Seth GSMC & KEM Hospital
Mumbai, India
All India Institute of Medical Sciences
New Delhi, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.